217,294 Shares in Viridian Therapeutics, Inc. $VRDN Acquired by Exome Asset Management LLC

Key Points

• Exome Asset Management LLC has acquired a $2.93 million position in Viridian Therapeutics, Inc., purchasing 217,294 shares and making it the firm's 14th largest investment.
• Viridian Therapeutics reported earnings of ($1.00) EPS for the last quarter with revenue of $0.08 million, which was in line with analysts' expectations.
• Recent analyst ratings for Viridian include a target price increase from Goldman Sachs from $27.00 to $30.00, alongside other firms adjusting their price targets, indicating a generally favorable outlook on the stock.

Exome Asset Management LLC purchased a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 217,294 shares of the company's stock, valued at approximately $2,929,000. Viridian Therapeutics makes up approximately 2.5% of Exome Asset Management LLC's investment portfolio, making the stock its 14th biggest holding. Exome Asset Management LLC owned about 0.27% of Viridian Therapeutics as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Amalgamated Bank raised its position in shares of Viridian Therapeutics by 49.7% during the 1st quarter. Amalgamated Bank now owns 2,531 shares of the company's stock valued at $34,000 after buying an additional 840 shares in the last quarter. Nuveen Asset Management LLC lifted its position in shares of Viridian Therapeutics by 198.2% during the fourth quarter. Nuveen Asset Management LLC now owns 681,012 shares of the company's stock worth $13,055,000 after purchasing an additional 452,627 shares during the last quarter. Principal Financial Group Inc. boosted its position in Viridian Therapeutics by 17.0% in the 1st quarter. Principal Financial Group Inc. now owns 208,836 shares of the company's stock valued at $2,815,000 after buying an additional 30,392 shares during the period. Rhumbline Advisers grew its stake in Viridian Therapeutics by 4.6% in the first quarter. Rhumbline Advisers now owns 104,559 shares of the company's stock worth $1,409,000 after purchasing an additional 4,621 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Viridian Therapeutics by 29.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 115,782 shares of the company's stock worth $2,220,000 after purchasing an additional 26,286 shares during the period.

Viridian Therapeutics Stock Down 4.0%

Shares of VRDN stock traded down $0.78 during trading hours on Friday, reaching $18.87. 448,146 shares of the company's stock were exchanged, compared to its average volume of 855,908. Viridian Therapeutics, Inc. has a 1 year low of $9.90 and a 1 year high of $27.20. The company has a current ratio of 11.01, a quick ratio of 11.01 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.54 billion, a PE ratio of -4.93 and a beta of 0.53. The stock's fifty day moving average price is $17.84 and its two-hundred day moving average price is $15.35.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($1.00) EPS for the quarter, hitting analysts' consensus estimates of ($1.00). The company had revenue of $0.08 million during the quarter, compared to analysts' expectations of $0.05 million. Viridian Therapeutics had a negative net margin of 112,806.88% and a negative return on equity of 78.95%. Viridian Therapeutics's revenue for the quarter was up 4.2% on a year-over-year basis. During the same period last year, the business earned ($0.81) EPS. Research analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on VRDN shares. Needham & Company LLC lowered their price target on shares of Viridian Therapeutics from $36.00 to $34.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. Wells Fargo & Company dropped their target price on Viridian Therapeutics from $27.00 to $26.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 7th. Oppenheimer boosted their price target on Viridian Therapeutics from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Thursday, August 7th. The Goldman Sachs Group boosted their target price on shares of Viridian Therapeutics from $27.00 to $30.00 and gave the stock a "buy" rating in a report on Thursday, August 7th. Finally, Jefferies Financial Group initiated coverage on shares of Viridian Therapeutics in a report on Monday, August 25th. They issued a "buy" rating and a $44.00 price target on the stock. Nine equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, Viridian Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.78.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.